HSBC Call 450 22UA 15.01.2025/ DE000HG5YGM5 /
5/15/2024 9:50:16 PM | Chg.0.000 | Bid10:00:11 PM | Ask10:00:11 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.001EUR | 0.00% | - Bid Size: - |
- Ask Size: - |
BIONTECH SE SPON. AD... | 450.00 - | 1/15/2025 | Call |
GlobeNewswire
4/22
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
GlobeNewswire
4/7
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...
GlobeNewswire
3/20
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire
3/20
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
GlobeNewswire
3/11
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...
GlobeNewswire
3/6
BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...
GlobeNewswire
2/8
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire
1/31
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjuga...
GlobeNewswire
1/22
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/...
GlobeNewswire
1/9
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
12/21/2023
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Can...
GlobeNewswire
12/18/2023
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
GlobeNewswire
11/6/2023
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
GlobeNewswire
10/26/2023
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Agains...
GlobeNewswire
10/23/2023
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advance...
GlobeNewswire
10/23/2023
BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to ...
GlobeNewswire
10/19/2023
BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial wit...
GlobeNewswire
10/16/2023
BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023